Voorbeelden van het gebruik van Dmards in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
DMARDs aren't working.
Switching between biological DMARDs.
DMARDs aren't working.
Dose modify concomitant DMARDs if appropriate.
All DMARDs have potential side effects.
Mensen vertalen ook
All patients received background non-biologic DMARDs.
Concomitant/sequential use of other DMARDs in rheumatoid arthritis.
combined with other DMARDs.
Some blood pressure medicines and DMARDs can harm the development of the foetus.
in combination with methotrexate or other DMARDs.
Patients receiving concomitant NSAIDs and conventional DMARDs were 72.6% and 70.2% respectively.
placebo were given every four weeks in combination with stable DMARDs.
Concomitant administration of hepatotoxic or haematotoxic DMARDs(e.g. methotrexate) is not advisable.
Decreases below 0.5 x 109/ l were reported in 0.3% patients receiving tocilizumab 8 mg/kg plus DMARDs.
When BRMs are combined with DMARDs, specifically methotrexate,
There is no experience with Cimzia in combination with DMARDs other than MTX.
Biologics and DMARDs are known for their effectiveness,
Approximately 20% of patients had received prior treatment with DMARDs other than MTX.
DMARDs may be prescribed for ankylosing spondylitis
taking Otezla alone and those also taking other DMARDs.
In rheumatoid arthritis Disease-modifying antirheumatic drugs(DMARDs) and Biologic response modifiers may be tried.
progressive RA in adults not previously treated with MTX or other DMARDs.
In the long-term open label extension studies, the rate of infections with RoActemra plus DMARDs was 116 events per 100 patient years exposure.
The long-term open label extension studies included 2,562 patients who received tocilizumab 8 mg/ kg with or without DMARDs.
Concomitant/ sequential use of other DMARDs The concomitant use of MabThera
in combination with MTX or other DMARDs.
In Study IV, tocilizumab was administered intravenously every 4 weeks in combination with other DMARDs vs. placebo and other DMARDs.
a documented history of psoriasis and had failed 1 or more DMARDs.
in combination with MTX or other DMARDs in the double-blind controlled period.
Fast-acting“first-line drugs” and slow-acting“second-line drugs” also referred to as disease-modifying antirheumatic drugs or DMARDs.